Edition:
United Kingdom

People: Clovis Oncology Inc (CLVS.OQ)

CLVS.OQ on NASDAQ Stock Exchange Global Select Market

20.22USD
5:17pm BST
Change (% chg)

$-0.66 (-3.16%)
Prev Close
$20.88
Open
$20.67
Day's High
$20.95
Day's Low
$20.15
Volume
87,320
Avg. Vol
587,292
52-wk High
$53.90
52-wk Low
$11.50

Spickschen, Thorlef 

Dr. Thorlef Spickschen is Independent Director of the Company. Dr. Spickschen was chairman of Biotest AG, a publicly-traded biotechnology company in Germany. From 1994 to 2001, he was chairman and chief executive officer of BASF Pharma/Knoll AG. From 1984 to 1994, Dr. Spickschen worked with Boehringer Mannheim GmbH, where he was responsible for sales and marketing and has been chairman of its Executive Board since 1990. From 1976 to 1984, Dr. Spickschen was Managing Director, Germany and Central Europe for Eli Lilly & Co. Dr. Spickschen is currently chairman of the advisory board of Heidelberg Innovation, a venture capital firm in life sciences/healthcare, and chairman of Verein Deutsche Nierenstiftung, sponsoring the German kidney foundation. Dr. Spickschen also served on the board of Pharmion Corporation from December 2001 through the company’s acquisition in 2008. Dr. Spickschen received a Doctorate in business management from the University of Cologne.

Basic Compensation

Total Annual Compensation, USD 55,000
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 439,579
Fiscal Year Total, USD 494,579

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

M. James Barrett

533,329

Patrick Mahaffy

8,726,480

Daniel Muehl

1,861,090

Gillian Ivers-Read

2,383,880

Lindsey Rolfe

2,429,680

Robert Azelby

--
As Of  31 Dec 2017